Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. United States
  4. Nyse
  5. Pfizer, Inc.
  6. News
  7. Summary
    PFE   US7170811035

PFIZER, INC.

(PFE)
  Report
Delayed Nyse  -  05/27 04:03:15 pm EDT
53.91 USD   -0.15%
05/27PFIZER INC : Berenberg sticks Neutral
MD
05/27ViiV Healthcare commits to grant voluntary licence for patents relating to cabotegravir long-acting for PrEP to Medicines Patent Pool
AQ
05/274D pharma Plans Phase 2 Trial for Metastatic Urothelial Carcinoma Maintenance Therapy
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

EU Medicines Watchdog to Issue Decision on Pfizer's COVID-19 Pill in January

01/24/2022 | 08:19am EDT
share with twitter
share with LinkedIn
share with facebook


© MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
MERCK & CO., INC. 0.83% 93.08 Delayed Quote.21.45%
PFIZER, INC. -0.15% 53.91 Delayed Quote.-8.70%
VALNEVA SE 3.16% 11.415 Real-time Quote.-53.41%
All news about PFIZER, INC.
05/27PFIZER INC : Berenberg sticks Neutral
MD
05/27ViiV Healthcare commits to grant voluntary licence for patents relating to cabote..
AQ
05/274D pharma Plans Phase 2 Trial for Metastatic Urothelial Carcinoma Maintenance Therapy
MT
05/26ZOOM VIDEO COMMUNICATIONS, INC. : An attempt to reconnect
05/26Pfizer Receives US FDA Fast Track Designation for Ervogastat/Clesacostat Combination to..
MT
05/26Malawi Among 5 First Five African Countries to Benefit From Pfizer Health Accord
AQ
05/26Pfizer Granted FDA Fast Track Designation for Ervogastat/Clesacostat Combination for th..
BU
05/26Pfizer Granted FDA Fast Track Designation for Ervogastat/Clesacostat Combination for th..
CI
05/26Pfizer Launches 'An Accord for a Healthier World' to Improve Health Equity for 1.2 Bill..
AQ
05/26Supreme Court says watchdogs should pay fees
AQ
More news
Analyst Recommendations on PFIZER, INC.
More recommendations
Financials (USD)
Sales 2022 104 B - -
Net income 2022 35 662 M - -
Net cash 2022 15 298 M - -
P/E ratio 2022 8,99x
Yield 2022 3,01%
Capitalization 302 B 302 B -
EV / Sales 2022 2,76x
EV / Sales 2023 3,56x
Nbr of Employees 79 000
Free-Float 58,2%
Chart PFIZER, INC.
Duration : Period :
Pfizer, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PFIZER, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Last Close Price 53,91 $
Average target price 57,50 $
Spread / Average Target 6,67%
EPS Revisions
Managers and Directors
Albert Bourla Chairman, Chief Executive & Operating Officer
David M. Denton Chief Financial Officer & Executive Vice President
Mikael Dolsten Executive VP, President-Research & Development
Lidia L. Fonseca Executive VP, Chief Digital & Technology Officer
Aida Habtezion Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
PFIZER, INC.-8.70%302 483
JOHNSON & JOHNSON5.86%476 521
ELI LILLY AND COMPANY17.11%291 184
ROCHE HOLDING AG-13.00%281 098
ABBVIE INC.10.78%265 067
NOVO NORDISK A/S0.49%241 552